Should You Buy GlaxoSmithKline plc Or AstraZeneca plc?

After releasing disappointing results today, is GlaxoSmithKline plc (LON: GSK) still a better buy than AstraZeneca plc (LON: AZN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKlineIt’s been a disappointing year thus far for investors in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), with shares in the pharmaceutical company being down 6%. This does not compare favourably to the wider market (the FTSE 100 is up 1%), nor to sector peer, AstraZeneca (LSE: AZN) (NYSE: AZN.US), which is up 23% having benefited from bid approaches from Pfizer.

A Challenging Quarter

Indeed, GlaxoSmithKline’s results released today showed that the company is struggling to come to terms with declining dales for its blockbuster inhaler, Advair. The removal of Advair from the reimbursement list of the US’s biggest prescription manager, Express Scripts, compounded falling sales for its omega 3 medicine, Lovaza, which is experiencing high levels of generic competition. The overall effect of this, as well as ongoing issues with regards to alleged bribery in China, has been a 4% reduction in revenue and a 12% fall in profit (after currency effects are removed).

A Different Story at AstraZeneca?

Meanwhile, sector peer AstraZeneca is also experiencing difficulties at present. Its patent cliff is in full-swing, with earnings for the full year expected to be 15% lower than last year, followed by a further 3% fall next year. This is in contrast to GlaxoSmithKline, which now expects flat earnings this year, with the market forecasting a rise of 9% next year.

However, investors are focused on the longer term for AstraZeneca, with the company’s strategy of acquisition in order to overcome its patent woes proving popular among investors. For GlaxoSmithKline, though, the focus is on a much shorter timeframe and the company’s enviable drugs pipeline is not the key motivator for investors right now when, in fact, it could be argued that it should be. That’s because it will be GlaxoSmithKline’s pipeline that will be the main driver of the company’s future growth.

Looking Ahead

Despite GlaxoSmithKline’s update being disappointing today, it continues to offer better growth prospects, a better valuation and a better yield than AstraZeneca. For instance, GlaxoSmithKline trades on a price to earnings (P/E) ratio of 13.5, while AstraZeneca’s P/E is 17.6. The two companies’ yields, meanwhile, are 5.4% (GlaxoSmithKline) and 3.8% (AstraZeneca), again highlighting that GlaxoSmithKline is the more attractive investment at the present time.

Certainly, the allegations regarding bribery in China are causing a certain amount of share price weakness, as are doubts regarding the loss of patent protection on key, blockbuster drugs. However, GlaxoSmithKline has a strong pipeline, growth potential, a top-notch yield and is trading at a significant discount to a key peer in AstraZeneca. As such, it appears to be a great buy at present with a bright long-term future ahead of it.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca and GlaxoSmithKline. The Motley Fool recommends GlaxoSmithKline.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »